Yesterday we published an analysis of the 21st annual symposium of the International Cannabinoid Research Society, held in St. Charles, Illinois July 5-10. We highlighted how researchers packed the program (.pdf) with talks not only about cannabis' palliative properties but also its curative efficacy. We also noted how the event, sponsored by the National Institute on Drug Abuse, was held the same week the DEA reiterated its stance that marijuana has no accepted medical use.
This federal duplicity slows the search for cures to breast, colon, prostate, and brain cancer, as well as Huntington's disease, Alzheimer's, and HIV, public health researchers say. Amanda Reiman, who holds a Ph.D from UC Berkeley's School of Social Welfare — where she is also a lecturer in addition to being BPG's director of research — presented a poster at the ICRS symposium. Reiman researches medical cannabis dispensaries as community health providers and the use of cannabis as a substitute for alcohol and other drugs. Combating the paucity of empirical data on dispensary populations, Reiman obtained survey information on thousands of patients going to Berkeley Patients Group over a year. The results are available after the jump.